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Abstract
The synthesis of a series of 9-ethyladenine derivatives bearing alkynyl chains in 2- or 8-position was undertaken, based on
the observation that replacement of the sugar moiety in adenosine derivatives with alkyl groups led to adenosine receptor
antagonists. All the synthesized compounds were tested for their affinity at human and rat A1,A 2A, and A3 adenosine
receptors in binding assays; the activity at the human A2B receptor was determined in adenylyl cyclase experiments.
Biological data showed that the 2-alkynyl derivatives possess good affinity and are slightly selective for the human A2A
receptor. The same compounds tested on the rat A1 and A2A subtypes showed in general lower affinity for both receptors.
On the other hand, the affinity of the 8-alkynyl derivatives at the human A1,A 2A, and A2B receptors proved to be lower
than that of the corresponding 2-alkynyl derivatives. On the contrary, the affinity of the same compounds for the human
A3 receptor was improved, resulting in A3 selectivity. As in the case of the 2-alkynyl-substituted compounds, the 8-
alkynyl derivatives showed decreased affinity for rat receptors. However, it is worthwhile to note that the 8-
phenylethynyl-9-ethyladenine was the most active compound of the two series (Ki in the nanomolar range) at both
thehuman and rat A3 subtype. Docking experiments of the 2- and 8-phenylethynyl-9-ethyladenines, at a rhodopsin-based
homology model, gave a rational explanation of the preference of the human A3 receptor for the 8-substituted compound.
Introduction
Adenosine is an autacoid involved in the regulation of
many aspects of cellular metabolism [1] and mediates its
effects through the activation of at least four human
receptors (P1), belonging to the superfamily of G protein-
coupled receptors, which have been recently cloned [2] and
classified as A1,A 2A,A 2B, and A3 [3]. All subtypes have
been cloned from a variety of species including the rat and
human. Species differences for the A3 adenosine receptor
(AdoR) are larger than for other AR subtypes, particularly
between rodent and human receptors (only 74% sequence
identity between rat and human A3 amino acid sequence)
[4]. This results in different affinities of ligands Y
particularly antagonists Y for rat versus human A3 receptors
[5, 6]. During the past decades many efforts have been
directed toward the discovery of potent and selective aden-
osine receptor ligands aimed at finding novel drugs [7].
Most adenosine agonists possess a structure very close to
that of the natural ligand adenosine; in contrast a wide
range of structural classes have been characterized as
adenosine receptor antagonists and developed as potential
therapeutic agents for CNS disorders, inflammatory dis-
eases, asthma, kidney failure and ischaemic injuries [8].
However, only a few xanthine antagonists as caffeine
and theophylline have been approved as drugs for their
CNS stimulating, diuretic, and bronchodilating effects,
respectively [8, 9].
In many papers it has been demonstrated that introduc-
tion of alkynyl chains in the 2-position of adenosine
derivatives led to compounds endowed with high affinity
at all adenosine receptors (AdoRs) [10Y15], whereas the
introduction of the same alkynyl chains in the 8-position
resulted in 8-alkynyladenosines, which were unable to
stimulate [
35S]GTPgS binding, and inhibited that stimu-
lated by NECA, yielded A3 antagonists [16, 17].
Moreover, we have published the synthesis and activities
for the human AdoR subtypes of a series of 9-ethyl-
adenines, substituted at the 2-, 6- and 8-positions, which
behaved as AdoR antagonists [18Y20]. In fact, replacement
of the sugar moiety of adenosine with a methyl group led
to a rather unselective antagonist of AdoR and adenine
itself is a weak adenosine antagonist [21].
Recently, substituted adenine derivatives, prepared as
hypoglycemic agents, were found to possess high potency
at the A2B AdoR subtype [22], whereas novel substituted
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6-cyclopentyladenine derivatives were characterized as
neutral antagonists endowed with high affinity for the A1
AdoR [23].
Hence, starting from these observations and in order to
widen our study on 9-ethyladenine derivatives, a series of
9-ethyladenines bearing alkynyl chains at the 2- or 8-




Synthesis of the 2- and 8-alkynyl-9-ethylpurines 2Y10,
12Y19, and 22
The synthesis of the 2-alkynyl-9-ethyladenines 2Y10 and 8-
alkynyl-9-ethyladenines 12Y19, was carried out starting
from 2-iodo-9-ethyladenine (1; [18] or 8-bromo-9-ethyl-
adenine (11; [18]), respectively, and are reported in
Schemes 1 and 2. In order to obtain the final products
compound 1 or 11 was reacted with the suitable terminal
alkynes using a modification of the palladium catalyzed
cross-coupling reaction [18].
However, for the synthesis of the 8-alkynyl derivative 22,
8-iodo-9-ethyladenine (21), obtained through the iodination
of the 9-ethyladenine (20) [18] with iodine and lithiumdi-
isopropylamide (LDA), was used as the starting material.
This choice was due to the fact that reaction of 8-bromo-
9-ethyladenine (11)w i t h( R,S)-phenylhydroxypropyne
failed to give the corresponding 8-phenylhydroxypropynyl
analogue, while the reaction was successful when the
8-iodo analogue was used as starting material.
The synthesis of the derivatives 3, 9, 13, and 19 has been
already published [18].
General synthetic procedures
Melting points were determined with a Bu ¨chi apparatus and
areuncorrected.
1H NMR spectra were obtained with Varian
Gemini 200 MHz or a Varian VXR 300-MHz spectrome-
ter; d in ppm, J in Hz. All exchangeable protons were con-
firmed by addition of D2O. TLC were carried out on pre-
coated TLC plates with silica gel 60 F-254 (Merck). For
column chromatography, silica gel 60 (Merck) was used.
Elemental analyses were determined on Carlo Erba model
1106 analyser and are within T0.4% of theoretical values.
General method for the synthesis of the 2- or 8-(ar)alkynyl-
9-ethyladenines 2, 4Y8, 10, 12, 14Y18 and 22
To a solution of 1, 11 or 21 (0.84 mmol) in dry DMF and
CH3CN [15 ml (1:2)], bis(triphenylphosphine)palladium
dichloride (12 mg, 0.017 mmol) and CuI (0.84 mg, 0.004
mmol), Et3N (3.4 ml), and the appropriate terminal alkyne
(4.2 mmol) were added. The reaction mixture was stirred
under an atmosphere of N2 at room temperature for the
time reported for each compound. The solvent was
removed in vacuo and the residue was chromatographed
on a silica gel column or TLC plates eluting with a suitable
mixture of solvents to give the desired derivatives 2, 4Y8,
10, 12, 14Y18 and 22.
9-Ethyl-2-pent-1-ynyl-9H-purin-6-ylamine (2). The reaction
of 1 with 1-pentyne for 24 h, followed by chromatography on
a silica gel column eluting with CHCl3YcC6H12YCH3OH
(88:10:2), gave 2 as a chromatographically pure amorphous
solid. Yield 51%, m.p. 105 -C( d e c ) ;
1H NMR (DMSO-d6)
d 0.97 (t, 3H, J =7 . 3H z ,C H 2CH3); 1.35 (t, 3H, J =7 . 0H z ,
NCH2CH3); 1.54 (m, 2H, CH2CH3); 2.35 (t, 2H, J =7 . 0H z ,
C K CCH2); 4.11 (q, 2H, J =7 . 2H z ,N CH2); 7.24 (s, 2H,
NH2); 8.15 (s, 1H, H-8). Anal. Calcd. for C12H15N5 (229.3):
C, 62.86; H, 6.59; N, 30.54. Found: C, 62.98; H, 6.73;
N, 30.25.
6-(6-Amino-9-ethyl-9H-purin-2-yl)-hex-5-yn-1-ol (4). The
reaction of 1 with 5-hexynyl-1-ol for 48 h, followed by
chromatography on a silica gel column eluting with
CH2Cl2YcC6H12YCH3OH (82:10:8), gave after crystalliza-
tion from EtOH, 4, as white crystals. Yield 83%, m.p.
138Y140 -C (dec);
1H NMR (DMSO-d6) d 1.35 (t, 3H,
J = 7.0 Hz, CH3); 1.54 (m, 4H, CH2CH2); 2.39 (m, 2H,
C K CCH2); 3.41 (m, 2H, CH2OH); 4.11 (q, 2H, J =7 . 2H z ,
NCH2); 4.42 (t, 1H, J =5 . 3H z ,C H 2OH); 7.26 (s, 2H, NH2);
8.16 (s, 1H, H-8). Anal. Calcd. for C13H17N5O( 2 5 9 . 3 ) :C ,
60.21; H, 6.61; N, 27.01. Found: C, 60.53; H, 6.79; N, 26.79.
2-Cyclohexylethynyl-9-ethyl-9H-purin-6-ylamine (5). The
reaction of 1 with cyclohexylacetylene for 20 h, followed
by chromatography on a silica gel column eluting with
CHCl3YCH3OH (99:1), gave, after crystallization from
EtOH, 5, as white crystals. Yield 62%, m.p. 203Y205 -C;
1H NMR (DMSO-d6) d 1.22Y1.87 (m, 8H, CH3 and H-
cyclohexyl); 2.59 (m, 1H, C K CCH); 4.12 (q, 2H, J = 7.2
Hz, NCH2); 7.26 (s, 2H, NH2); 8.16 (s, 1H, H-8). Anal.
Calcd. for C15H19N5 (269.3): C, 66.89; H, 7.11; N, 26.00.
Found: C, 67.13; H, 7.45; N, 25.77.
2-Cyclohex-1-enylethynyl-9-ethyl-9H-purin-6-ylamine
(6). The reaction of 1 with 1-ethynylcyclohexene for 20 h,
followed by chromatography on a silica gel column eluting Scheme 1
174 R. Volpini et al.with CHCl3YCH3OH (98:2), gave, after crystallization from
MeOH, 6, as white crystals. Yield 90%, m.p. 9 250 -C;
1H
NMR (DMSO-d6) d 1.39 (t, 3H, J = 7.2 Hz, CH3); 1.62 (m,
4H, H-cyclohexenyl); 2.15 (m, 4H, H-cyclohexenyl); 4.15
(q, 2H, J = 7.5 Hz, NCH2); 6.30 (m, 1H, CH = C); 7.35 (bs,
2H, NH2); 8.21 (s, 1H, H-8). Anal. Calcd. for C15H17N5
(267.3): C, 67.39; H, 6.41; N, 26.20. Found: C, 67.68; H,
6.80; N, 26.01.
9-Ethyl-2-phenylethynyl-9H-purin-6-ylamine (7). The re-
action of 1 with 1-phenylacetylene for 6 h, followed by
chromatography on a silica gel column eluting with
CH2Cl2YCH3OH (99.5:0.5), gave, after crystallization from
EtOH, 7, as white crystals. Yield 85%, m.p. 250 -C (dec);
1H NMR (DMSO-d6) d 1.38 (t, 3H, J = 7.5 Hz, CH3); 4.16
(q, 2H, J = 7.2 Hz, CH2); 7.43 (m, 5H, H-Ph and NH2);
7.58 (m, 2H, H-Ph); 8.23 (s, 1H, H-8). Anal. calcd. for
C15H13N5 (263.3): C, 68.42; H, 4.98; N, 26.60. Found: C,
68.78; H, 5.27; N, 26.35.
1-[4-(6-Amino-9-ethyl-9H-purin-2-ylethynyl)-phenyl]-
ethanone (8). The reaction of 1 with 1-(4-ethynylphenyl)
ethanone for 6 h, followed by chromatography on a silica
gel column eluting with CH2Cl2YcC6H12YCH3OH
(85:10:15), gave, after crystallization from EtOH, 8,a s
white crystals. Yield 67%, m.p. 9 230 -C;
1H NMR
(DMSO-d6) d 1.39 (t, 3H, J = 7.3 Hz, CH2CH3); 2.59 (s,
3H, COCH3); 4.17 (q, 2H, J = 7.5 Hz, CH2CH3); 7.46 (s,
2H, NH2); 7.72 (d, 2H, J = 8.2 Hz, H-Ph); 7.98 (d, 2H, J =
8.2 Hz, H-Ph); 8.25 (s, 1H, H-8). Anal. Calcd. for
C17H15N5O (305.3): C, 66.87; H, 4.95; N, 22.94. Found:
C, 66.98; H, 5.24; N, 22.78.
3-(6-Amino-9-ethyl-9H-purin-2-yl)-1-phenyl-prop-2-yn-1-
ol (10). The reaction of 1 with (R,S)-1-phenyl-2-propyn-
1-ol for 20 h, followed by chromatography on a silica gel
column eluting with CHCl3YCH3OH (96:4), gave, after
crystallization from EtOH, 10, as white crystals. Yield
57%, m.p. 9 250 -C;
1H NMR (DMSO-d6) d 1.36 (t, 3H,
J = 6.9 Hz, CH3); 4.13 (q, 2H, J = 7.2 Hz, CH2); 5.58 (d,
1H, J = 6.0 Hz, CHOH); 6.24 (d, 1H, J = 6.0 Hz, CHOH);
7.36 (m, 5H, H-Ph and NH2); 7.51 (d, 2H, J = 8.4 Hz, H-
Ph); 8.19 (s, 1H, H-8). Anal. calcd. for C16H15N5O (293.3):
C, 65.52; H, 5.15; N, 23.88. Found: C, 65.90; H, 5.29; N,
23.61.
9-Ethyl-8-pent-1-ynyl-9H-purin-6-ylamine (12). The re-
action of 11 with 1-pentyne for 48 h, followed by
chromatography on a silica gel column eluting with
CHCl3YCH3OH (98:2), gave, after crystallization from
MeOH, 12, as white crystals. Yield 73%, m.p. 182Y184
-C;
1H NMR (DMSO-d6) d 1.04 (t, 3H, J = 7.2 Hz,
CH2CH3); 1.35 (t, 3H, J =7 . 2H z ,N C H 2CH3); 1.64 (m, 2H,
CH2CH3); 2.57 (t, 2H, J =6 . 9H z ,CK CCH2); 4.20 (q, 2H,
J = 7.2 Hz, NCH2); 7.37 (bs, 2H, NH2); 8.16 (s, 1H, H-2).
Anal. Calcd. for C12H15N5 (229.3): C, 62.86; H, 6.59; N,
30.54. Found: C, 63.14; H, 6.84; N, 30.27.
6-(6-Amino-9-ethyl-9H-purin-8-yl)-hex-5-yn-1-ol
(14). The reaction of 11 with 5-hexynyl-1-ol for 48 h,
followed by chromatography on a silica gel column eluting
with CHCl3YCH3OH (95:5), gave, after crystallization
from MeOH, 14, as white crystals. Yield 73%, m.p.
162Y164 -C;
1H NMR (DMSO-d6) d 1.35 (t, 3H, J = 7.2
Hz, CH3); 1.63 (m, 4H, CH2CH2); 2.60 (t, 2H, J = 6.6 Hz,
C K CCH2); 3.46 (m, 2H, CH2OH); 4.20 (q, 2H, J = 7.5 Hz,
NCH2); 4.48 (t, 1H, J = 5.1 Hz, OH); 7.36 (bs, 2H, NH2);
8.16 (s, 1H, H-2). Anal. Calcd. for C13H17N5O (259.3): C,
60.21; H, 6.61; N, 27.01. Found: C, 60.49; H, 6.83; N,
26.76.
Scheme 2
Purine derivatives as adenosine receptor ligands 1758-Cyclohexenylethynyl-9-ethyl-9H-purin-6-ylamine
(15). The reaction of 11 with cyclohexylacetylene for
24 h, followed by chromatography on a silica gel column
eluting with CHCl3YcC6H12YCH3OH (55:40:5), gave after
crystallization from MeOH, 15, as white crystals. Yield
85%, m.p. 247 -C (dec);
1H NMR (DMSO-d6) d 1.26Y1.83
(m, 13H, H-cyclohexyl and CH3); 2.79 (m, 1H, CHYCKC);
4.15 (q, 2H, J = 7.1 Hz, NYCH2); 7.33 (bs, 2H, NH2); 8.11
(s, 1H, H-2). Anal. Calcd. for C15H19N5 (269.3): C, 66.89;
H, 7.11; N, 26.00. Found: C, 67.25; H, 7.41; N, 25.79.
8-Cyclohex-1-enylethynyl-9-ethyl-9H-purin-6-ylamine
(16). The reaction of 11 with 1-ethynylcyclohexene for
36 h, followed by chromatography on a silica gel column
eluting with CHCl3YCH3OH (99:1), gave, after crystalli-
zation from MeOH, 16, as white crystals. Yield 65%, m.p.
160 -C (dec);
1H NMR (DMSO-d6) d 1.36 (t, 3H, J = 7.2
Hz, CH3); 1.64 (m, 4H, H-cyclohexenyl); 2.21 (m, 4H, H-
cyclohexenyl); 4.21 (q, 2H, J = 7.2 Hz, NCH2); 6.47 (m,
1H, CH = C); 7.43 (bs, 2H, NH2); 8.18 (s, 1H, H-2). Anal.
Calcd. for C15H17N5 (267.3): C, 67.39; H, 6.41; N, 26.20.
Found: C, 67.74; H, 6.56; N, 26.03.
9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine (17). The
reaction of 11 with 1-phenylacetylene for 72 h, followed
by chromatography on a silica gel column eluting with
CH2Cl2YcC6H12YCH3OH (85:10:5), gave, after crystalli-
zation from MeOH, 17, as white crystals. Yield 52%, m.p.
249Y251 -C;
1H NMR (DMSO-d6) d 1.43 (t, 3H, J = 7.2
Hz, CH3); 4.33 (q, 2H, J = 7.3 Hz, NCH2); 7.53 (m, 5H, H-
Ph and NH2); 7.72 (m, 2H, H-Ph); 8.21 (s, 1H, H-2). Anal.
Calcd. for C15H13N5 (263.3): C, 68.42; H, 4.98; N, 26.60.
Found: C, 68.77; H, 5.35; N, 26.43.
1-[4-(6-Amino-9-ethyl-9H-purin-8-ylethynyl)-phenyl]-
ethanone (18). The reaction of 11 with 1-(4-ethynyl-
phenyl) ethanone for 16 h, followed by chromatography on
a silica gel column eluting with CHCl3YCH3OH (90:10),
gave, after crystallization from MeOH, 18,a sw h i t e
crystals. Yield 40%, m.p. 9 250 -C;
1H NMR (DMSO-
d6) d 1.42 (t, 3H, J = 6.9 Hz, CH2CH3); 2.63 (s, 3H,
COCH3); 4.34 (q, 2H, J = 6.9 Hz, CH2); 7.52 (bs, 2H,
NH2); 7.85 (d, 2H, J = 8.4 Hz, H-Ph); 8.06 (d, 2H, J =8 . 4
Hz, H-Ph); 8.21(s, 1H, H-2). Anal. Calcd. for C17H15N5O
(305.3): C, 66.87; H, 4.95; N, 22.94. Found: C, 67.23; H,
5.25; N, 22.78.
3-(6-Amino-9-ethyl-9H-purin-8-yl)-1-phenyl-prop-2-yn-1ol
(22). The reaction of 21 with (R,S)-1-phenyl-2-propyn-1-
ol for 36 h, followed by chromatography on a silica gel
column eluting with CHCl3YCH3OH (96:4), gave, after
crystallization from CH3CNYMeOH, 22, as white crystals.
Yield 13%, m.p. 226Y228 -C;
1H NMR (DMSO-d6) d 1.33
(t, 3H, J = 7.2 Hz, CH3); 4.21 (q, 2H, J = 7.2 Hz, NCH2);
5.77 (d, 1H, J = 6.1 Hz, CHOH); 6.49 (d, 1H, J = 6.1 Hz,
CHOH); 7.41 (m, 5H, H-Ph and NH2); 7.59 (m, 2H, H-Ph);
8.19 (s, 1H, H-2). Anal. Calcd. for C16H15N5O (293.3): C,
65.52; H, 5.15; N, 23.88. Found: C, 65.81; H, 5.27; N,
23.50.
9-Ethyl-8-iodo-9H-purin-6-ylamine (21)
To a solution of 2.2 ml (15.7 mmol) of freshly distilled
diisopropylamime and 6.0 ml of dry THF, in a three
necked round bottom flask, under a flux of N2, were added
dropwise 9.8 ml (15.7 mmol) of butyllithium (1.6 M in
hexane). The mixture was kept under stirring at r.t. for 15
min. After that, the mixture was cooled at j70 -C and 500
mg (3.1 mmol) of 20, dissolved in 10 ml of dry THF, were
added, and after 1 h a solution of iodine (4.9 mmol) in 10
ml of dry THF was added dropwise.
After 1 h more at j70 -C 4 drops of glacial acetic acid
and 3 ml of methanol were added. The mixture was
allowed to warm at r. t., the solvent was removed in vacuo
and the residue was chromatographed on a silica gel
column eluting with CHCl3YCH3OH (98:2) to give, after
crystallization from MeOH, 21, as white crystals. Yield
56%, m.p. 247Y249 -C;
1H NMR (DMSO-d6) d 1.31 (t, 3H,
J = 7.2 Hz, CH3); 4.12 (q, 2H, J = 7.2 Hz, CH2); 7.33 (br s,
2H, NH2); 8.08 (s, 1H, H-2). Anal. Calcd. for C7H8IN5
(289.1): C, 29.08; H, 2.79; N, 24.23. Found: C, 29.44; H,
2.97; N, 24.02.
Biological evaluation
Binding studies and adenylyl cyclase activity at human
adenosine receptors
The radioligand binding experiments were carried out
exactly as described previously [24]. For A1 adenosine
receptor binding 1 nM [
3H]CCPA was used as a radio-
ligand, whereas 30 and 10 nM [
3H]NECA was used for
A2A and A3 receptors, respectively. Non specific binding
was determined in the presence of 1 mM theophylline (A1)
or 100 mM R-PIA (A2A and A3). Ki values were calculated
from competition curves by nonlinear curve fitting with the
program SCTFIT [25]. CHO cells stably transfected with
human adenosine receptors were grown adherently and
maintained in Dulbecco’s Modified Eagles Medium with
nutrient mixture F12 (DMEM/F12) without nucleosides,
containing 10% fetal calf serum, penicillin (100 U/ml),
streptomycin (100 mg/ml), L-glutamine (2 mM) and
Geneticin (G-418, 0.2 mg/ml) at 37 -Ci n5 %C O 2/95%
air as described earlier [24].
For radioligand binding studies and measurement of
adenylyl cyclase activity crude membrane fractions were
prepared from fresh or frozen cells with two different
protocols which were described recently [24].
Determination of adenylyl cyclase activity followed the
procedure described by [24]. IC50 values for the inhibition
of cyclase stimulated with 5 mM NECA were calculated
with the Hill equation and converted to Ki values with the
Cheng and Prusoff equation [24]. The Hill slopes were near
unity suggesting a competitive interaction of the antago-
nists tested.
Binding studies at rat adenosine receptors
A1 and A2A receptor binding: Displacement of [
3H]CHA
(31 Ci/mmol) from A1 adenosine receptor in rat cortical
membranes and of [
3H]CGS 21680 (42.1 Ci/mmol) from
rat striatal membranes were performed as described [26].
176 R. Volpini et al.[
125I]AB-MECA binding to A3 receptor of rat testis
membranes was performed in 50 mM Tris, 10 mM MgCl2
and 1 mM EDTA buffer (pH 7.4) containing 0.2 mg of
proteins and 25 nM DPCPX, to selectively block A1
receptor subtypes. Incubations were carried out for 90 min
at 25 -C. Non-specific binding was determined in the
presence of 50 mM R-PIA and accounted to 30% of total
binding. Binding reaction was terminated by rapid filtra-
tion through a Whatman GF/C filter, washing three times
with 5 ml of ice-cold buffer.
All compounds were routinely dissolved in DMSO and
diluted with assay buffer to the final concentration,
where the amount of DMSO never exceeded 2%. At
least 6 different concentrations of each compound were
used and IC50 values were computer-generated using non-
linear regression formula on a computer program (Graph-
Pad, San Diego, CA). IC50 values were converted to Ki
values, knowing the Kd values of radioligands in the
different tissues and using the Cheng and Prusoff equation




125I]AB-MECA were 1.2, 10 and 1.35 nM,
respectively.
Molecular modeling studies
All the calculations were carried out utilizing the Hyper-
Chem 7.2 program (Hypercube, Gainesville, Florida,
USA). For molecular mechanics calculations the AMBER
96 [28] force field was utilized with a distance-dependent
dielectric constant scaled by a factor of 4. All the energy
minimizations were carried out employing the
PolakYRibiere conjugate gradient. All molecular dynamics
simulations were carried at a constant temperature of 298
K, using a timestep of 1 fs. Before the simulation, the
system, virtually at 0 K, was slowly (1 ps) heated until it
reached the simulation temperature.
The human A3 model used for the docking experiments
was the rhodopsin-based homology model previously
constructed by us [17].
2-Phenylethynyl-9-ethyladenine (7) and 8-phenyle-
thynyl-9-ethyladenine (17) were docked into the receptor
helical bundle by modifying the ligands in A3/2-phenyl-
ethynyladenosine or A3/8-phenylethynyladenosine com-
plex [17], respectively.
After applying a harmonic restraint of 7 kcal/mol to the
backbone atoms of the protein, the receptor/ligand com-
plexes were submitted to energy minimization (RMS G 0.5
kcal/mol/A ˚ ), 10 ps of molecular dynamics, and energy
minimization (RMS G 0.001 kcal/mol/A ˚ ).
Results and discussion
Binding studies
All the compounds were evaluated at the human recombi-
nant adenosine receptors, stably transfected into Chinese
hamster ovary (CHO) cells, utilizing radioligand binding
studies (A1,A 2A,A 3) or adenylyl cyclase activity assay




radioligand for A1 receptors, whereas [
3H]NECA (5¶-N-
ethylcarboxamidoadenosine) was used for the A2A and A3
subtypes [24]. In the case of A2B receptors Ki values were
calculated from IC50 values determined by inhibition of
NECA-stimulated adenylyl cyclase activity.
The compounds were also tested for their affinity at rat











Ki values are in mM with 95% confidence intervals in
parentheses. The results are shown in Table 1.
Biological data showed that the 2-alkynyl derivatives
possess good affinity at all human adenosine receptors and
are slightly selective for the A2A subtype.
Compounds 5 and 10 bearing a cyclohexylethyne and a
phenylhydroxypropyne in 2-position, respectively, resulted
in the most active of the series with Ki in the low
nanomolar range both at human A1 and A2A receptors (5;
Ki A1 = 0.080 mM, Ki A2A = 0.037 mM, and 10; Ki A1 =
0.098 mM, Ki A2A = 0.035 mM).
At the A2B receptor the derivatives bearing linear chains
in 2-position showed functional activity in the mM range
(2; Ki A2B =1 7mM, 3; Ki A2B =1 2mM, and 4; Ki A2B =1 9
mM), while the presence of sterically hindered substituents
in the same position was detrimental for the activity.
However, the presence of a phenylhydroxypropynyl chain
seems to facilitate the interaction with the A2B subtype, in
fact the 2-phenylhydroxypropynyl-9-ethyladenine resulted
the most active compound of the two series (10; Ki A2B =
1.4 mM). This finding is in agreement with our previous
results obtained with the corresponding adenosine de-
rivative. In fact, the (R,S)-2-phenyhydroxypropynyl-N-
ethylcarboxamidoadenosine [(R,S)-PHPNECA, EC50 A2B =
1.1 mM] resulted in one of the most potent agonist with
nucleoside structure at human A2B receptors reported so far
[14, 29].
The affinity of the 2-alkynyl derivatives for the A3
subtype was lower than that at A1 and A2A receptors.
The same compounds, tested on the rat A1 and A2A
subtypes, showed in general lower affinity for the rat A2A
receptor, while compounds 7Y9, bearing an aromatic ring
in the 2-position, showed slightly higher affinity at the
rat A1 receptor, compared to the corresponding human
receptor, hence resulting slightly A1 selective (7; Ki A1
(r) = 0.43 mMv sKi A1 (h) = 0.77 mM, 8; Ki A1 (r) = 1.9 mM
vs Ki A1 (h) = 8.3 mM, and 9; Ki A1 (r) = 0.15 mMv sKi A1
(h) = 0.21 mM,). As in the case of human receptors, com-
pounds 5 and 10 showed the highest affinity both at rat
A1 and A2A subtypes (5; Ki A1 =0 . 0 7 2mM, Ki A2A =
0.069 mM, and 10; Ki A1 =0 . 1 4mM, Ki A2A =0 . 1 4mM).
At the rat A3 receptor these compounds showed
comparable affinity to that at human one.
As far as the 8-alkynyl derivatives, their affinity at the
human A1,A 2A, and A2B receptors proved to be lower than
Purine derivatives as adenosine receptor ligands 177Table 1. Affinities of 2- and 8-alkynyl-9-ethyladenines in radioligand binding assays at human and rat A1,A 2A, and A3 adenosine receptors and effects
on adenylate cyclase activity at human A2B adenosine receptor.
a






2 Y(CH2)2YCH3 1.2 (h) 0.76 (h) 17 (h) 2.1 (h)
(1.0Y1.5) (0.43Y1.3) (11Y27) (1.2Y3.9)
4.6 (r) 2.9 (r) 8% at 10 mM (r)
(3.9Y5.7) (2.5Y3.4)
3 Y(CH2)3YCH3 0.55 (h) 0.42 (h) 12 (h) 2.3 (h)
(0.24Y1.2) (0.26Y0.69) (5.9Y27) (1.1Y4.9)
0.98 (r) 0.72 (r) 1.3 (r)
(0.59Y1.4) (0.63Y0.81) (0.78Y2.0)
4 Y(CH2)4YOH 3.6 (h) 1.9 (h) 19(h) 14 (h)
(2.9Y4.6) (1.1Y3.3) (10Y35) (6.5Y32)
12 (r) 4.4 (r) 17% at 10 mM (r)
(10Y14) (3.5Y5.4)
5 Ycyclohexyl 0.080 (h) 0.037 (h) Q 30 (h) 3.6 (h)
(0.056Y0.11) (0.026Y0.053) (2.8Y4.8)
0.072 (r) 0.069 (r) 1.0 (r)
(0.060Y0.080) (0.063Y0.081) (0.46Y2.2)
6 Ycyclohexenyl 0.18 (h) 0.35 (h) 930 (h) 0.39 (h)
(0.14Y0.21) (0.27Y0.45) (0.25Y0.61)
0.17 (r) 0.80 (r) 3.5 (r)
(0.14Y0.20) (0.75Y0.86) (3.1Y3.9)
7 YC6H5 0.77 (h) 0.40 (h) 930 (h) 0.52 (h)
(0.36Y1.6) (0.24Y0.67) (0.35Y0.78)
0.43 (r) 0.81 (r) 3.0 (r)
(0.35Y0.51) (0.67Y0.96) (0.97Y6.2)
8 YC6H4Yp-COCH3 8.3 (h) 3.8 (h) 930 (h) 9100 (h)
(5.1Y14) (1.9Y7.7)
1.9 (r) 5.8 (r) 11% at 10 mM (r)
(1.5Y2.4) (4.6Y7.1)
9 Y(CH2)2YC6H5 0.21 (h) 0.15 (h) 930.0 (h) 4.1 (h)
(0.12Y0.39) (0.091Y0.23) (2.9Y5.6)
0.15 (r) 2.7 (r) 4.8 (r)
(0.09Y0.24) (2.0Y3.4) (4.4Y5.3)
10 (R,S)-CH(OH)C6H5 0.098 (h) 0.035 (h) 1.4 (h) 4.3 (h)
(0.092Y0.10) (0.018Y0.072) (0.85Y2.3) (3.0Y6.2)
0.14 (r) 0.14 (r) 1.2 (r)
(0.11Y0.17) (0.10Y0.21) (0.58Y2.0)
12 Y(CH2)2YCH3 0.064 (h) 0.37 (h) 2.7 (h) 0.59 (h)
(0.025Y0.17) (0.27Y0.50) (2.5Y2.9) (0.22Y1.6)
0.24 (r) 1.4 (r) 1.5 (r)
(0.17Y0.32) (1.1Y1.8) (1.1Y1.9)
13 Y(CH2)3YCH3 2.3 (h) 0.44 (h) 22 (h) 0.62 (h)
(1.4Y3.9) (0.22Y0.87) (11Y45) (0.34Y1.1)
4.6 (r) 0.82 (r) 3.5 (r)
(3.6Y5.7) (0.72Y0.94) (2.8Y4.2)
14 Y(CH2)4YOH 6.5 (h) 1.6 (h) 21 (h) 6.6 (h)
(5.5Y7.5) (0.84Y3.0) (19Y24) (3.5Y12)
12% a 10 mM (r) 13 (r) 23 (r)
(8.8Y18) (18Y29)
15 Ycyclohexyl 0.60 (h) 0.36 (h) 9100 (h) 2.2 (h)
(0.48Y0.69) (0.11Y0.43) (1.5Y2.7)
nd (r) nd (r) nd (r)
16 Ycyclohexenyl 1.2 (h) 2.0 (h) 9100 (h) 0.43 (h)
(0.66Y2.1) (1.2Y3.4) (0.23Y0.80)
1.0 (r) 3.8 (r) 2.2 (r)
(0.68Y1.4) (3.1Y4.5) (1.9Y4.0)
178 R. Volpini et al.that of the corresponding 2-alkynyl analogues, with the
exception of compound 12 (12; Ki A1 =0 . 0 6 4mM, Ki A2A =
0.37 mM, Ki A2B =2 . 7mM, and Ki A3 =0 . 5 9mMv s2 ;Ki
A1 =1 . 2mM, Ki A2A =0 . 7 6mM, Ki A2B =1 7mM, and Ki
A3 =2 . 1mM).
However, it is worthwhile to note that the derivatives,
which showed some activity at the A2B receptor, are those
bearing linear chains in the 8-position, as in the case of the
2-substituted compounds (12; Ki A2B = 2.7 mM, 13; Ki
A2B =2 2mM, and 14; Ki A2B =2 1mM).
On the contrary, the affinity of the 8-alkynyl derivatives
for the human A3 receptor, compared to the corresponding
2-substituted derivatives, was improved; hence the 8-
phenylethynyl-9-ethyladenine (17) with a Ki A3 (h) of
0.086 and 0.25 mM (r) resulted the most active compound
of the two series at both the human and rat A3 subtype and
was A3 selective.
As in the case of the 2-substituted compound, the 8-
alkynyl derivatives showed decreased affinity for rat
receptors. The selectivity of this series of derivatives for
the A1,A 2A,a n dA 3 receptor subtypes was strictly
correlated to the nature of the alkynyl chain, and there is
a good correlation between affinity at human and rat
receptors.
Molecular modeling
In order to get an insight into the mechanism of the ligand
recognition and to give a rational explanation of the
preference of the human A3 receptor for the 8-substituted
compounds rather than the 2-substituted compounds in this
series, we carried out docking experiments of 2-phenyl-
ethynyl-9-ethyladenine (7) and 8-phenylethynyl-9-ethyl-
adenine (17) at a rhodopsin-based homology model of the
receptor (Figure 1).
In a previous molecular modeling study [17], we
proposed that 2- and 8-alkynyl derivatives of adenosine
bind to the human A3 receptor in a way that the C2 of a
molecule matches the C8 of the other one, with a good
steric and electrostatic overlap of the purine moieties and
the alkynyl chains.
On the basis of the structure activity relationships data,
we hypothesized a similar binding mode for the alkynyl
derivatives of adenosine and the correspondent 9-ethyl-
adenine analogues. The results of our docking experiments
were in good agreement with the biological data, confirm-
ing the soundness of the hypothesis on which they were
based.
In the case of the adenosine derivatives, the compounds
substituted at the 2-position were endowed with higher
affinity than the correspondent 8-substituted analogues. In
fact, in the latter case the sugar moiety had unfavourable
interactions with the receptor.
On the other hand, in the case of the 2- and 8-
phenylethynyl-9-ethyladenine, due to the substitution of
the ribose moiety with the less bulky ethyl group, the
negative ligand receptor interactions were eliminated
even in the case of the 8-substituted compound. Accord-
ing to the results of the present study, in both situations
the ethyl group is accommodated in the hydrophobic
17 YC6H5 1.3 (h) 0.60 (h) Q 30 (h) 0.086 (h)
(0.94Y1.7) (0.64Y1.1) (0.067Y0.11)
2.6 (r) 0.64 (r) 0.25 (r)
(2.0Y3.3) (0.48Y0.82) (0.12Y0.43)
18 YC6H4Yp-COCH3 9100 (h) 25 930 (h) 9100 (h)
(13Y47)
10% a 10 mM (r) 5.4 (r) 5% a 10 mM (r)
(4.0Y7.0)
19 Y(CH2)2YC6H5 4.6 (h) 1.6 (h) 9100 (h) 3.2 (h)
(2.6Y8.1) (0.75Y3.5) (2.2Y4.7)
2.5 (r) 2.7 (r) 5.3 (r)
(1.4Y4.0) (1.0Y2.5) (3.4Y7.6)
22 (R,S)-CH(OH)C6H5 3.0 (h) 0.88 (h) Q30.0 (h) 3.7 (h)
(1.6Y5.6) (0.55Y1.4) (2.9Y4.6)
4.0 (r) 0.94 (r) 2.1(r)
(2.3Y6.1) (0.68Y1.2) (1.3Y3.0)
aSpecies are given in brackets: h = human, r = rat. Ki values are in mM with 95% confidence intervals in parentheses.
bDisplacement of specific [
3H]CCPA binding in CHO cells, stably transfected with human recombinant A1 adenosine receptor, and displacement of
specific [
3H]CHA binding in rat cortical membranes or percentage of inhibition of specific binding at 10 mM concentration.
cDisplacement of specific [
3H]NECA binding in CHO cells, stably transfected with human recombinant A2A adenosine receptor, and displacement of
specific [
3H]CGS 21680 binding in rat striatal membranes.
dMeasurement of receptor-stimulated adenylyl cyclase activity in CHO cells, stably transfected with human recombinant A2B adenosine receptor. Ki
values were calculated from IC50 values determined by inhibition of NECA-stimulated adenylyl cyclase activity.
eDisplacement of specific [
3H]NECA binding in CHO cells, stably transfected with human recombinant A3 adenosine receptor, and displacement of
specific [
125I]AB-MECA binding in rat testis membranes or percentage of inhibition of specific binding at 10 mM concentration.
Table 1. Continued.
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transmembrane domain (TM3). Furthermore, the bind-
ing of the 8-alkynyl derivative to the A3 receptor
appears to be facilitated by a stronger electrostatic
interaction of the crucial Asn 250 (TM6) with the adenine
ring compared to the case of the 2-alkynyl derivatives
(Figure 1).
Conclusions
With this study we have demonstrated that it is possible to
modulate the activity at the adenosine receptor subtypes by
introducing alkynyl chains in the 2- or 8-position of the 9-
ethyladenine.
Although all the synthesized compounds were more
active at human receptors, it is worthwhile to note that, in
the series of the 2-substituted derivatives, compounds 5
and 10 are the ones endowed with the highest affinity at
both human and rat A1 and A2A receptors.
The same trend has been observed with the 8-substituted
derivatives: in fact the 8-phenylethynyl-9-ethyladenine
(17) proved to be the most active and selective compound
of the two series at human and rat A3 subtype.
From these results it is possible to conclude that the
selectivity of these two series of derivatives for the A1,
A2A, and A3 receptor subtypes is strictly correlated to the
nature of the alkynyl chain, and that there is a good
correlation between the affinity at human and rat receptors.
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